ArticleActa diabetologica2023
Seven basement membrane-specific expressed genes are considered potential biomarkers for the diagnosis and treatment of diabetic nephropathy.
Article in Acta diabetologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Disulfidptosis: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Linderalactone mitigates diabetic renal injury by inhibiting macrophage inflammation via the Dectin1/Syk/CARD9/IRF5/NF-κB pathway.Journal of diabetes investigation · 2026Article
- Risk stratification in diabetic kidney disease: a review of prediction models for methodological advances and clinical application.Journal of translational medicine · 2026Review
- Identification and validation of epithelial‑mesenchymal transition‑related genes for diabetic nephropathy by WGCNA and machine learning.Molecular medicine reports · 2025Article
- SPP1 + macrophages facilitate pancreatic cancer progression via ITGB6-mediated interactions: evidence from integrated multi-omics analysis and experimental validation.Immunologic research · 2025Article
- Extracellular matrix in vascular homeostasis and disease.Nature reviews. Cardiology · 2025Review
- Identification of Genes Associated with Familial Focal Segmental Glomerulosclerosis Through Transcriptomics and In Silico Analysis, IncludingInternational journal of molecular sciences · 2024Article
- The immune-inflammation factor is associated with diabetic nephropathy: evidence from NHANES 2013-2018 and GEO database.Scientific reports · 2024Article
- LncRNA SNHG14 silencing attenuates the progression of diabetic nephropathy via the miR-30e-5p/SOX4 axis.Journal of diabetes · 2024Article
- Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease.Antioxidants (Basel, Switzerland) · 2024Review
- Identification of basement membrane markers in diabetic kidney disease and immune infiltration by using bioinformatics analysis and experimental verification.IET systems biology · 2023Article
- Cordycepin from Cordyceps militaris ameliorates diabetic nephropathy via the miR-193b-5p/MCL-1 axis.Chinese medicine · 2023Article
- Screening of hub inflammatory bowel disease biomarkers and identification of immune-related functions based on basement membrane genes.European journal of medical research · 2023Article
- Identification and validation of disulfidptosis-related gene signatures and their subtype in diabetic nephropathy.Frontiers in genetics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsDiabetic nephropathy (DN) is a diabetes-related chronic vasculitis. DN diminishes kidney function over time and, of course, leads to end stage renal disease in people (ESRD). In spite of the advances in diagnostic and treatment methods for DN, DN continues to impose a significant physical and psychological burden on patients, severely impacting their quality of life, making the hunt for novel therapeutic targets necessary.
methodsThe Gene Expression Omnibus (GEO) microarray datasets GSE1009, GSE30122, GSE142153, and GSE96804 were downloaded to identify differentially expressed genes (DEGs) in kidney tissues from patients in the DN group and normal controls. These three datasets were examined for genes associated with basement membranes (BMs) with differential gene expression. The target genes were then subjected to gene ontology (GO) annotation and Kyoto Gene and Genome Encyclopedia (KEGG) pathway enrichment analysis. BM-related genes underwent PPI network analysis and screening of the top 10 hub genes, along with immune infiltration analysis and column line graph model development. Finally, we conducted DN therapeutic medication prediction and the creation of something like a miRNA network for genetic markers with BMs.
resultsSeven candidate BM-related genes (COL4A1, COL4A2, COL6A2, COL6A3, FN1, ITGQ4, and LAMB1) with acceptable helps the healthcare were discovered. Enrichment analysis of diabetes-related genes event occurred the role of biological processes including extracellular matrix organization, extracellular structural organization, and collagen-containing extracellular matrix, as well as the PI3K-Akt signaling pathway and the AGE-RAGE signaling pathway, in diabetic complications. These genes may also be associated in immune cells and autoimmune activities, such as Macrophages and MHC class I, in order to impact the immune process in DN. In the meanwhile, based on these seven BM-related genes, we discovered that Ginsenoside Rh1 was very significant for drug targeting.
conclusionsThis research identified seven BM-related genes as possible diagnostic and therapeutic biomarkers for DN. Analysis of inflammatory infiltration indicated that these genes may be important in inflammatory processes through Macrophages and MHC class I, hence impacting the course and development of DN illness. The development of a correlated column line graph model for it also shown excellent predictive capabilities. In addition, we have found pharmaceuticals, such as Ginsenoside Rh1, that may provide fresh insights into the personalized management of patients with DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.